Anpario (LSE:ANP), an independent manufacturer of natural animal feed additives, said revenue and profit for the year to date are ahead of the prior year and in line with full-year analyst consensus, which expects revenue of £50.3m, adjusted EBITDA of £10.3m and net cash of £16.9m.
Chairman Matthew Robinson flagged strong trading in the Middle East, including first sales of new product AmpLIPhy, alongside continued growth in the US across both the Bio-Vet and Anpario ranges and in Australasia.
The group said it had absorbed an initial spike in logistics costs but has since passed higher ongoing freight charges to customers under its standard trading terms.
Raw material price inflation in its acid-based eubiotic range, which accounts for around 20% of sales, has been addressed through targeted price increases, and the company said gross margins in the first half are consistent with the second half of 2025.
Cash stood at £10.9m as at 31 May, down from £12.4m at the end of December, with £1.1m of that movement attributable to the company's share buyback programme.
Interim results for the six months to 30 June are due on 9 September.
